The Experts below are selected from a list of 4554 Experts worldwide ranked by ideXlab platform

Thomas Pettke - One of the best experts on this subject based on the ideXlab platform.

  • δ98 95mo values and molybdenum concentration data for nist srm 610 612 and 3134 towards a Common Protocol for reporting mo data
    Geostandards and Geoanalytical Research, 2012
    Co-Authors: Nicolas D Greber, Christopher Siebert, Thomas F Nagler, Thomas Pettke
    Abstract:

    Molybdenum concentration and δ98/95Mo values for NIST SRM 610 and 612 (solid glass), NIST SRM 3134 (lot 891307; liquid) and IAPSO seawater reference material are presented based on comparative measurements by MC-ICP-MS performed in laboratories at the Universities of Bern and Oxford. NIST SRM 3134 and NIST SRM 610 and 612 were found to have identical and homogeneous 98Mo/95Mo ratios at a test portion mass of 0.02 g. We suggest, therefore, that NIST SRM 3134 should be used as reference for the δ–Mo notation and to employ NIST SRM 610 or 612 as solid silicate secondary measurement standards, in the absence of an isotopically homogeneous solid geological reference material for Mo. The δ98/95MoJMC Bern composition (Johnson Matthey ICP standard solution, lot 602332B as reference) of NIST SRM 3134 was 0.25 ± 0.09‰ (2s). Based on five new values, we determined more precisely the mean open ocean δ98/95MoSRM 3134 value of 2.09 ± 0.07‰, which equals the value of δ98/95MoJMC Bern of 2.34 ± 0.07‰. We also refined the Mo concentration data for NIST SRM 610 to 412 ± 9 μg g−1 (2s) and NIST SRM 612 to 6.4 ± 0.7 μg g−1 by isotope dilution. We propose these concentration data as new working values, which allow for more accurate in situ Mo determination using laser ablation ICP-MS or SIMS.

  • δ98/95Mo values and Molybdenum Concentration Data for NIST SRM 610, 612 and 3134: Towards a Common Protocol for Reporting Mo Data
    Geostandards and Geoanalytical Research, 2012
    Co-Authors: Nicolas D Greber, Christopher Siebert, Thomas F Nagler, Thomas Pettke
    Abstract:

    Molybdenum concentration and δ98/95Mo values for NIST SRM 610 and 612 (solid glass), NIST SRM 3134 (lot 891307; liquid) and IAPSO seawater reference material are presented based on comparative measurements by MC-ICP-MS performed in laboratories at the Universities of Bern and Oxford. NIST SRM 3134 and NIST SRM 610 and 612 were found to have identical and homogeneous 98Mo/95Mo ratios at a test portion mass of 0.02 g. We suggest, therefore, that NIST SRM 3134 should be used as reference for the δ–Mo notation and to employ NIST SRM 610 or 612 as solid silicate secondary measurement standards, in the absence of an isotopically homogeneous solid geological reference material for Mo. The δ98/95MoJMC Bern composition (Johnson Matthey ICP standard solution, lot 602332B as reference) of NIST SRM 3134 was 0.25 ± 0.09‰ (2s). Based on five new values, we determined more precisely the mean open ocean δ98/95MoSRM 3134 value of 2.09 ± 0.07‰, which equals the value of δ98/95MoJMC Bern of 2.34 ± 0.07‰. We also refined the Mo concentration data for NIST SRM 610 to 412 ± 9 μg g−1 (2s) and NIST SRM 612 to 6.4 ± 0.7 μg g−1 by isotope dilution. We propose these concentration data as new working values, which allow for more accurate in situ Mo determination using laser ablation ICP-MS or SIMS.

Uwe Haberkorn - One of the best experts on this subject based on the ideXlab platform.

  • 68ga psma 11 pet ct in patients with recurrent prostate cancer a modified Protocol compared with the Common Protocol
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Fabian Haupt, Silvan Boxler, Tobias Gross, Lotte Dijkstra, Viktor Fech, Helle D. Zacho, Ian Alberts, Christos Sachpekidis, Tim Hollandletz, Uwe Haberkorn
    Abstract:

    PURPOSE: 68Ga-PSMA-11 PET/CT is Commonly performed at 1 h post injection (p.i.). However, various publications have demonstrated that most prostate cancer (PC) lesions exhibit higher contrast at later imaging. The aim of this study was to compare the "Common" Protocol of 68Ga-PSMA-11 PET/CT with a modified Protocol. METHODS: In 2017, we used the following scanning Protocol for 68Ga-PSMA-11 PET/CT in patients with recurrent PC: acquisition at 1 h p.i. without further preparations. From 2018, all scans were conducted at 1.5 h p.i. In addition, patients were orally hydrated with 1 L of water 0.5 h p.i. and were injected with 20 mg of furosemide 1 h p.i. Both Protocols including 112 patients (2017) and 156 (modified Protocol in 2018) were retrospectively compared. Rates of pathologic scans, maximum standardized uptake values (SUVmax), and tumor contrast (ratio lesion-SUVmax/background-SUVmean) as well as average standardized uptake values (SUVmean) of urinary bladder were analyzed. RESULTS: Both tumor contrast and tracer uptake were significantly (p 0.5-≤ 2.0 ng/ml. Average SUVmean of the urinary bladder was significantly (p < 0.001) lower with the modified Protocol. CONCLUSIONS: The modified Protocol, which includes a combination of delayed image acquisition at 1.5 h p.i., hydration, and furosemide resulted in higher tumor contrast and seems to have the potential to increase the rates of pathological scans, especially at low PSA levels.

  • ^68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer—a modified Protocol compared with the Common Protocol
    European Journal of Nuclear Medicine and Molecular Imaging, 2019
    Co-Authors: Fabian Haupt, Silvan Boxler, Tobias Gross, Lotte Dijkstra, Viktor Fech, Tim Holland-letz, Helle D. Zacho, Ian Alberts, Christos Sachpekidis, Uwe Haberkorn
    Abstract:

    Purpose^68Ga-PSMA-11 PET/CT is Commonly performed at 1 h post injection (p.i.). However, various publications have demonstrated that most prostate cancer (PC) lesions exhibit higher contrast at later imaging. The aim of this study was to compare the “CommonProtocol of ^68Ga-PSMA-11 PET/CT with a modified Protocol.MethodsIn 2017, we used the following scanning Protocol for ^68Ga-PSMA-11 PET/CT in patients with recurrent PC: acquisition at 1 h p.i. without further preparations. From 2018, all scans were conducted at 1.5 h p.i. In addition, patients were orally hydrated with 1 L of water 0.5 h p.i. and were injected with 20 mg of furosemide 1 h p.i. Both Protocols including 112 patients (2017) and 156 (modified Protocol in 2018) were retrospectively compared. Rates of pathologic scans, maximum standardized uptake values (SUVmax), and tumor contrast (ratio lesion-SUVmax/background-SUVmean) as well as average standardized uptake values (SUVmean) of urinary bladder were analyzed.ResultsBoth tumor contrast and tracer uptake were significantly ( p < 0.001) higher in the novel Protocol. Although statistically not significant, the rates of pathologic scans were also higher in the modified Protocol: 76.3% vs. 68.8% for all PSA values including 38.9% vs. 25.0% for PSA < 0.5 ng/ml and 60.0% vs. 56.7% for PSA > 0.5–≤ 2.0 ng/ml. Average SUVmean of the urinary bladder was significantly ( p < 0.001) lower with the modified Protocol.ConclusionsThe modified Protocol, which includes a combination of delayed image acquisition at 1.5 h p.i., hydration, and furosemide resulted in higher tumor contrast and seems to have the potential to increase the rates of pathological scans, especially at low PSA levels.

  • 68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer-a modified Protocol compared with the Common Protocol.
    European Journal of Nuclear Medicine and Molecular Imaging, 2019
    Co-Authors: Fabian Haupt, Silvan Boxler, Tobias Gross, Lotte Dijkstra, Viktor Fech, Tim Holland-letz, Helle D. Zacho, Ian Alberts, Christos Sachpekidis, Uwe Haberkorn
    Abstract:

    PURPOSE: 68Ga-PSMA-11 PET/CT is Commonly performed at 1 h post injection (p.i.). However, various publications have demonstrated that most prostate cancer (PC) lesions exhibit higher contrast at later imaging. The aim of this study was to compare the "Common" Protocol of 68Ga-PSMA-11 PET/CT with a modified Protocol. METHODS: In 2017, we used the following scanning Protocol for 68Ga-PSMA-11 PET/CT in patients with recurrent PC: acquisition at 1 h p.i. without further preparations. From 2018, all scans were conducted at 1.5 h p.i. In addition, patients were orally hydrated with 1 L of water 0.5 h p.i. and were injected with 20 mg of furosemide 1 h p.i. Both Protocols including 112 patients (2017) and 156 (modified Protocol in 2018) were retrospectively compared. Rates of pathologic scans, maximum standardized uptake values (SUVmax), and tumor contrast (ratio lesion-SUVmax/background-SUVmean) as well as average standardized uptake values (SUVmean) of urinary bladder were analyzed. RESULTS: Both tumor contrast and tracer uptake were significantly (p 0.5-≤ 2.0 ng/ml. Average SUVmean of the urinary bladder was significantly (p < 0.001) lower with the modified Protocol. CONCLUSIONS: The modified Protocol, which includes a combination of delayed image acquisition at 1.5 h p.i., hydration, and furosemide resulted in higher tumor contrast and seems to have the potential to increase the rates of pathological scans, especially at low PSA levels.

Nicolas D Greber - One of the best experts on this subject based on the ideXlab platform.

  • δ98 95mo values and molybdenum concentration data for nist srm 610 612 and 3134 towards a Common Protocol for reporting mo data
    Geostandards and Geoanalytical Research, 2012
    Co-Authors: Nicolas D Greber, Christopher Siebert, Thomas F Nagler, Thomas Pettke
    Abstract:

    Molybdenum concentration and δ98/95Mo values for NIST SRM 610 and 612 (solid glass), NIST SRM 3134 (lot 891307; liquid) and IAPSO seawater reference material are presented based on comparative measurements by MC-ICP-MS performed in laboratories at the Universities of Bern and Oxford. NIST SRM 3134 and NIST SRM 610 and 612 were found to have identical and homogeneous 98Mo/95Mo ratios at a test portion mass of 0.02 g. We suggest, therefore, that NIST SRM 3134 should be used as reference for the δ–Mo notation and to employ NIST SRM 610 or 612 as solid silicate secondary measurement standards, in the absence of an isotopically homogeneous solid geological reference material for Mo. The δ98/95MoJMC Bern composition (Johnson Matthey ICP standard solution, lot 602332B as reference) of NIST SRM 3134 was 0.25 ± 0.09‰ (2s). Based on five new values, we determined more precisely the mean open ocean δ98/95MoSRM 3134 value of 2.09 ± 0.07‰, which equals the value of δ98/95MoJMC Bern of 2.34 ± 0.07‰. We also refined the Mo concentration data for NIST SRM 610 to 412 ± 9 μg g−1 (2s) and NIST SRM 612 to 6.4 ± 0.7 μg g−1 by isotope dilution. We propose these concentration data as new working values, which allow for more accurate in situ Mo determination using laser ablation ICP-MS or SIMS.

  • δ98/95Mo values and Molybdenum Concentration Data for NIST SRM 610, 612 and 3134: Towards a Common Protocol for Reporting Mo Data
    Geostandards and Geoanalytical Research, 2012
    Co-Authors: Nicolas D Greber, Christopher Siebert, Thomas F Nagler, Thomas Pettke
    Abstract:

    Molybdenum concentration and δ98/95Mo values for NIST SRM 610 and 612 (solid glass), NIST SRM 3134 (lot 891307; liquid) and IAPSO seawater reference material are presented based on comparative measurements by MC-ICP-MS performed in laboratories at the Universities of Bern and Oxford. NIST SRM 3134 and NIST SRM 610 and 612 were found to have identical and homogeneous 98Mo/95Mo ratios at a test portion mass of 0.02 g. We suggest, therefore, that NIST SRM 3134 should be used as reference for the δ–Mo notation and to employ NIST SRM 610 or 612 as solid silicate secondary measurement standards, in the absence of an isotopically homogeneous solid geological reference material for Mo. The δ98/95MoJMC Bern composition (Johnson Matthey ICP standard solution, lot 602332B as reference) of NIST SRM 3134 was 0.25 ± 0.09‰ (2s). Based on five new values, we determined more precisely the mean open ocean δ98/95MoSRM 3134 value of 2.09 ± 0.07‰, which equals the value of δ98/95MoJMC Bern of 2.34 ± 0.07‰. We also refined the Mo concentration data for NIST SRM 610 to 412 ± 9 μg g−1 (2s) and NIST SRM 612 to 6.4 ± 0.7 μg g−1 by isotope dilution. We propose these concentration data as new working values, which allow for more accurate in situ Mo determination using laser ablation ICP-MS or SIMS.

T. Eisaka - One of the best experts on this subject based on the ideXlab platform.

Fabian Haupt - One of the best experts on this subject based on the ideXlab platform.

  • 68ga psma 11 pet ct in patients with recurrent prostate cancer a modified Protocol compared with the Common Protocol
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Fabian Haupt, Silvan Boxler, Tobias Gross, Lotte Dijkstra, Viktor Fech, Helle D. Zacho, Ian Alberts, Christos Sachpekidis, Tim Hollandletz, Uwe Haberkorn
    Abstract:

    PURPOSE: 68Ga-PSMA-11 PET/CT is Commonly performed at 1 h post injection (p.i.). However, various publications have demonstrated that most prostate cancer (PC) lesions exhibit higher contrast at later imaging. The aim of this study was to compare the "Common" Protocol of 68Ga-PSMA-11 PET/CT with a modified Protocol. METHODS: In 2017, we used the following scanning Protocol for 68Ga-PSMA-11 PET/CT in patients with recurrent PC: acquisition at 1 h p.i. without further preparations. From 2018, all scans were conducted at 1.5 h p.i. In addition, patients were orally hydrated with 1 L of water 0.5 h p.i. and were injected with 20 mg of furosemide 1 h p.i. Both Protocols including 112 patients (2017) and 156 (modified Protocol in 2018) were retrospectively compared. Rates of pathologic scans, maximum standardized uptake values (SUVmax), and tumor contrast (ratio lesion-SUVmax/background-SUVmean) as well as average standardized uptake values (SUVmean) of urinary bladder were analyzed. RESULTS: Both tumor contrast and tracer uptake were significantly (p 0.5-≤ 2.0 ng/ml. Average SUVmean of the urinary bladder was significantly (p < 0.001) lower with the modified Protocol. CONCLUSIONS: The modified Protocol, which includes a combination of delayed image acquisition at 1.5 h p.i., hydration, and furosemide resulted in higher tumor contrast and seems to have the potential to increase the rates of pathological scans, especially at low PSA levels.

  • ^68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer—a modified Protocol compared with the Common Protocol
    European Journal of Nuclear Medicine and Molecular Imaging, 2019
    Co-Authors: Fabian Haupt, Silvan Boxler, Tobias Gross, Lotte Dijkstra, Viktor Fech, Tim Holland-letz, Helle D. Zacho, Ian Alberts, Christos Sachpekidis, Uwe Haberkorn
    Abstract:

    Purpose^68Ga-PSMA-11 PET/CT is Commonly performed at 1 h post injection (p.i.). However, various publications have demonstrated that most prostate cancer (PC) lesions exhibit higher contrast at later imaging. The aim of this study was to compare the “CommonProtocol of ^68Ga-PSMA-11 PET/CT with a modified Protocol.MethodsIn 2017, we used the following scanning Protocol for ^68Ga-PSMA-11 PET/CT in patients with recurrent PC: acquisition at 1 h p.i. without further preparations. From 2018, all scans were conducted at 1.5 h p.i. In addition, patients were orally hydrated with 1 L of water 0.5 h p.i. and were injected with 20 mg of furosemide 1 h p.i. Both Protocols including 112 patients (2017) and 156 (modified Protocol in 2018) were retrospectively compared. Rates of pathologic scans, maximum standardized uptake values (SUVmax), and tumor contrast (ratio lesion-SUVmax/background-SUVmean) as well as average standardized uptake values (SUVmean) of urinary bladder were analyzed.ResultsBoth tumor contrast and tracer uptake were significantly ( p < 0.001) higher in the novel Protocol. Although statistically not significant, the rates of pathologic scans were also higher in the modified Protocol: 76.3% vs. 68.8% for all PSA values including 38.9% vs. 25.0% for PSA < 0.5 ng/ml and 60.0% vs. 56.7% for PSA > 0.5–≤ 2.0 ng/ml. Average SUVmean of the urinary bladder was significantly ( p < 0.001) lower with the modified Protocol.ConclusionsThe modified Protocol, which includes a combination of delayed image acquisition at 1.5 h p.i., hydration, and furosemide resulted in higher tumor contrast and seems to have the potential to increase the rates of pathological scans, especially at low PSA levels.

  • 68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer-a modified Protocol compared with the Common Protocol.
    European Journal of Nuclear Medicine and Molecular Imaging, 2019
    Co-Authors: Fabian Haupt, Silvan Boxler, Tobias Gross, Lotte Dijkstra, Viktor Fech, Tim Holland-letz, Helle D. Zacho, Ian Alberts, Christos Sachpekidis, Uwe Haberkorn
    Abstract:

    PURPOSE: 68Ga-PSMA-11 PET/CT is Commonly performed at 1 h post injection (p.i.). However, various publications have demonstrated that most prostate cancer (PC) lesions exhibit higher contrast at later imaging. The aim of this study was to compare the "Common" Protocol of 68Ga-PSMA-11 PET/CT with a modified Protocol. METHODS: In 2017, we used the following scanning Protocol for 68Ga-PSMA-11 PET/CT in patients with recurrent PC: acquisition at 1 h p.i. without further preparations. From 2018, all scans were conducted at 1.5 h p.i. In addition, patients were orally hydrated with 1 L of water 0.5 h p.i. and were injected with 20 mg of furosemide 1 h p.i. Both Protocols including 112 patients (2017) and 156 (modified Protocol in 2018) were retrospectively compared. Rates of pathologic scans, maximum standardized uptake values (SUVmax), and tumor contrast (ratio lesion-SUVmax/background-SUVmean) as well as average standardized uptake values (SUVmean) of urinary bladder were analyzed. RESULTS: Both tumor contrast and tracer uptake were significantly (p 0.5-≤ 2.0 ng/ml. Average SUVmean of the urinary bladder was significantly (p < 0.001) lower with the modified Protocol. CONCLUSIONS: The modified Protocol, which includes a combination of delayed image acquisition at 1.5 h p.i., hydration, and furosemide resulted in higher tumor contrast and seems to have the potential to increase the rates of pathological scans, especially at low PSA levels.